Navigation Links
Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
Date:9/18/2008

WALTHAM, Mass. and DANVILLE, Pa., Sept. 18 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), and Geisinger Health System, today announced a research collaboration to explore the role of genetics in obesity. The goal of the collaboration is to develop a series of genetic tests that will help physicians better understand an individual's inherited resistance to weight loss and, more specifically, gauge a patient's likelihood of success with diet and other weight loss techniques.

Geisinger and Interleukin Genetics will engage in a case-control retrospective study involving the analysis of DNA to better understand genetic links to obesity. The study will focus exclusively on variations of perilipin, interleukin 1 and a select number of other genes.

"We are pleased to be working with Geisinger to develop an accurate and affordable genetic test as a predictor of weight loss success," commented Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. "This relationship allows our scientists to build on Geisinger's extensive clinical expertise and biobank."

"We are excited to be working with Interleukin Genetics and view our collaboration with them as a way to capitalize on our integrated health system and electronic infrastructure to conduct research in new ways," said David Carey, Ph.D., Associate Chief Research Officer of Geisinger.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com

About Geisinger Health System

Founded in 1915, Geisinger Health System (Danville, PA) is one of the nation's largest integrated health services organizations. Serving more than two million residents throughout central and northeastern Pennsylvania, the physician-led organization is at the forefront of the country's rapidly emerging electronic health records movement. Geisinger is comprised of three medical center campuses, a 700-member group practice, a not-for-profit health insurance company and the Center for Health Research -- dedicated to creating innovative new models for patient care, satisfaction and clinical outcomes. For more information, visit http://www.geisinger.org

About Obesity & Weight Management

Obesity has been defined by the National Institutes of Health (NIH) as a BMI of 30 and above; a BMI of 30 is about 30 pounds overweight. Obesity is often multi-factorial, based on both genetic and behavioral factors. Accordingly, treatment of obesity usually requires more than just dietary changes. Exercise, counseling, support, and sometimes medication can supplement diet to help patients conquer weight problems. Being overweight is a significant contributor to health problems. It increases the risk of developing a number of diseases. Because obesity is associated with increased risk for a range of chronic conditions, healthcare costs are higher for obese individuals than for normal weight individuals. Annual medical expenditures are $732 higher on average for obese individuals than for normal weight individuals. The annual cost of managing obesity in the United States alone amounts to approximately $100 billion of which approximately $52 billion are direct costs of healthcare. These costs amount to approximately 5.7 percent of all U.S. health expenditure. The cost of lost productivity due to obesity is approximately $3.9 billion, and another $33 billion is spent annually on weight-loss products and services.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
2. Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition
3. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
8. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
9. New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
10. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
11. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... ... us, but there are things we can do to improve the odds of staying healthy for ... that there are simple, yet important steps that can be taken to maintain good health and ... her patients include;, , exercise , healthy diet , ...
(Date:4/29/2016)... ... 30, 2016 , ... World Patent Marketing , a ... an automotive invention that improves the storage features of a pick up truck. ... Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over the next ...
(Date:4/29/2016)... , ... April 29, 2016 , ... In an ... and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent in ... youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial ... for Graduate Medical Education (ACGME) that it has received accreditation for its residency ... of three residency programs that Memorial is currently pursuing, including Pediatrics and Internal ...
(Date:4/29/2016)... ... 2016 , ... Our bodies are bombarded daily by environmental and lifestyle factors ... stressors is to adopt a more healthful diet, but too many people think that ... Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, ...
Breaking Medicine News(10 mins):